• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Muscarinic cholinergic receptor subtypes in hippocampus in human cognitive disorders.

作者信息

Smith C J, Perry E K, Perry R H, Candy J M, Johnson M, Bonham J R, Dick D J, Fairbairn A, Blessed G, Birdsall N J

机构信息

Department of Neuropathology Research, Newcastle General Hospital, Newcastle upon Tyne, U.K.

出版信息

J Neurochem. 1988 Mar;50(3):847-56. doi: 10.1111/j.1471-4159.1988.tb02990.x.

DOI:10.1111/j.1471-4159.1988.tb02990.x
PMID:3339358
Abstract

Total muscarinic receptor levels, the levels of the subtypes exhibiting high and low affinity for pirenzepine, and the high- and low-affinity agonist states of the receptor were investigated in hippocampal tissue obtained at autopsy from mentally normal individuals and the following pathological groups: Alzheimer's disease, Parkinson's disease, Down's syndrome, alcoholic dementia, Huntington's chorea, and motor-neurone disease. A moderate decrease in the density of both high-affinity pirenzepine and high-affinity agonist subtypes was found in Alzheimer's disease, whereas a trend towards an increase in the overall muscarinic receptor density was apparent in the parkinsonian patients without dementia, mainly due to an increase in the low-affinity agonist state; the differences between the Alzheimer's disease and nondemented parkinsonian cases were highly significant. As previously reported, the levels of both choline acetyltransferase and acetylcholinesterase were markedly reduced in both Alzheimer's disease and Parkinson's disease--with a greater loss of both enzymes in the demented subgroup of parkinsonian patients. Activities of the cholinergic enzymes were also extensively reduced in Down's syndrome, accompanied by a loss of high-affinity pirenzepine binding. There were no significant receptor or enzyme alterations in the other groups studied. These observations suggest that in the human brain, extensive degeneration of cholinergic axons to the hippocampus, as indicated by a loss of cholinergic enzymes, is not necessarily accompanied by extensive muscarinic receptor abnormalities (as might be expected if a major subpopulation were presynaptic). Moreover, the opposite changes in muscarinic binding in Parkinson's and Alzheimer's diseases may be related to the greater severity of dementia in the latter disease.

摘要

相似文献

1
Muscarinic cholinergic receptor subtypes in hippocampus in human cognitive disorders.
J Neurochem. 1988 Mar;50(3):847-56. doi: 10.1111/j.1471-4159.1988.tb02990.x.
2
Cholinergic receptors in cognitive disorders.认知障碍中的胆碱能受体
Can J Neurol Sci. 1986 Nov;13(4 Suppl):521-7. doi: 10.1017/s0317167100037240.
3
Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types.阿尔茨海默病、帕金森病和路易体痴呆类型中胆碱能烟碱受体和毒蕈碱受体
J Neural Transm Park Dis Dement Sect. 1990;2(3):149-58. doi: 10.1007/BF02257646.
4
Parallel postnatal development of choline acetyltransferase activity and muscarinic acetylcholine receptors in the rat olfactory bulb.大鼠嗅球中胆碱乙酰转移酶活性与毒蕈碱型乙酰胆碱受体的平行产后发育
J Neurochem. 1986 Mar;46(3):671-80. doi: 10.1111/j.1471-4159.1986.tb13024.x.
5
Regional distribution of muscarinic and nicotinic cholinergic receptor binding activities in the human brain.毒蕈碱型和烟碱型胆碱能受体结合活性在人脑内的区域分布。
J Chem Neuroanat. 1989 Jul-Aug;2(4):189-99.
6
Cortical muscarinic receptor subtypes and Alzheimer's disease.皮质毒蕈碱受体亚型与阿尔茨海默病
Lancet. 1982 Dec 4;2(8310):1277. doi: 10.1016/s0140-6736(82)90129-5.
7
Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies.阿尔茨海默病中高亲和力激动剂与M1毒蕈碱受体结合的丧失:对胆碱能替代疗法失败的影响。
Ann Neurol. 1991 Mar;29(3):256-62. doi: 10.1002/ana.410290305.
8
Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease.
J Neurochem. 1988 Jun;50(6):1914-23. doi: 10.1111/j.1471-4159.1988.tb02497.x.
9
Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia.帕金森病患者中与痴呆相关的毒蕈碱结合及胆碱乙酰转移酶活性
Brain Res. 1982 Jan 28;232(1):129-39. doi: 10.1016/0006-8993(82)90615-1.
10
Regional distribution of M1, M2 and non-M1, non-M2 subtypes of muscarinic binding sites in rat brain.大鼠脑中毒蕈碱结合位点M1、M2以及非M1、非M2亚型的区域分布
J Pharmacol Exp Ther. 1990 Dec;255(3):1148-57.

引用本文的文献

1
Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome.唐氏综合征 Ts65Dn 小鼠模型中的胆碱能衰老。
Neurochem Res. 2022 Oct;47(10):3076-3092. doi: 10.1007/s11064-022-03659-0. Epub 2022 Jun 29.
2
The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain.衰老大脑中谷氨酸能、胆碱能和多巴胺能信号传导的生物学与病理生物学
Front Aging Neurosci. 2021 Jul 13;13:654931. doi: 10.3389/fnagi.2021.654931. eCollection 2021.
3
Regulation of synaptic plasticity in a schizophrenia model.
精神分裂症模型中突触可塑性的调节
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13301-6. doi: 10.1073/pnas.0506034102. Epub 2005 Aug 30.
4
Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography.
Eur J Nucl Med. 1997 Jun;24(6):602-8. doi: 10.1007/BF00841396.
5
Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study.
Psychopharmacology (Berl). 1995 Sep;121(2):231-41. doi: 10.1007/BF02245634.
6
Deficits in iodine-labelled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzheimer's disease.阿尔茨海默病患者中碘标记的3-喹核醇基苯甲酸酯结合与脑血流量的关系缺陷。
Eur J Nucl Med. 1993 May;20(5):379-86. doi: 10.1007/BF00208995.